The price of empagliflozin, a commonly prescribed diabetes drug, has been slashed by a staggering 90% in India. This ...
Homegrown pharmaceutical companies launching significantly cheaper generic versions of empagliflozin—a widely prescribed SGLT2 inhibitor for type-2 diabetes ...
The price of commonly used diabetes drug empagliflozin has been slashed by almost one-tenth, with the entry of its generic ...
Mankind Pharma, Alkem Laboratories, Glenmark are some of the companies to have launched, making the drug affordable to most ...
Several domestic drug makers, including Mankind Pharma, have launched the diabetes drug Empagliflozin at significantly ...
MT Newswires on MSN2d
Indian Markets End Lower on Wednesday as IT Stocks WeighIndian equity benchmarks ended slightly lower on Wednesday as a decline in information technology stocks on US growth ...
Glenmark Pharmaceuticals has launched Empagliflozin, a widely recognized SGLT2 inhibitor, in India. The drug has been introduced under the brand name Glempa (Empagliflozin 10/25 mg), along with its ...
Generic versions of diabetes drug Empagliflozin launched in India, crashing prices by 80-90% on day one post-patent expiry.
Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...
Glenmark launches Empagliflozin and combinations in India under Glempa brand, aiming to improve glycemic control and reduce ...
Glenmark Pharmaceuticals on Wednesday said it has launched a medication for glycemic control and weight-loss for diabetes ...
Glenmark Pharmaceuticals launches Empagliflozin, an SGLT2 inhibitor, in India under the brand name Glempa for glycemic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback